- The QQ1 2025 quarter (fiscal period ended 2025-03-31) for Acro Biomedical Co Ltd shows no reported revenue and a net loss of $10,301 (units in thousands implied by the data set). Operating loss of $8,934 and interest expense of $1,367 drive the bottom line, yielding an EPS of -0.0002 on 60.04 million weighted-average shares. The company posted an extremely limited expense base (SG&A and operating expenses reported as $8,934) alongside no realized revenue, indicating a low-activity period or early-stage commercialization cycle.
- Liquidity and balance sheet health are very challenging. The current ratio and quick ratio are both 0.0147, and the cash ratio is 0.000763, signaling an acute liquidity constraint relative to near-term obligations. Cash per share is minimal at $0.0000042. These metrics imply a fragile runway unless the company secures external funding or accelerates cash-generating activities.
- On a relative basis, several valuation and leverage indicators are unfavorable or ambiguous (e.g., enterprise value multiple -25.26, price-to-book -0.198, price-to-earnings -1.457). The absence of reported revenue and the negative bottom-line result contrast sharply with more mature peers in healthcare biotech, underscoring high risk, high-variance dynamics.
- The absence of an earnings call transcript in the provided data precludes management-quote-driven color. Investors should seek the full transcript or supplemental commentary to enrich interpretation of R&D progress, partnerships, and strategic plans. The near-term thesis hinges on capital markets activity, regulatory milestones, and any nascent commercial traction or licensing arrangements.